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Abstract
Purpose: To identify potential molecular targets for lung cancer intervention and di‐
agnosis,	we	analyzed	the	differential	miRNA	expression	of	peripheral	blood	between	
lung cancer patients and healthy controls.
Methods: Three pairs of cases’ and controls’ peripheral blood samples were evaluated 
for	miRNA	expression	by	microarray.	12	miRNAs	were	selected	for	RT‐PCR	validation	
and	target	genes	prediction.	In	addition,	4	miRNAs	were	selected	for	future	validation	
by	RT‐PCR	in	a	large	sample	of	145	cases	and	55	frequency‐matched	healthy	controls.
Results: A	total	of	338	differentially	expressed	miRNAs	were	screened	and	identified	
by	microarray.	According	to	the	fold	changes,	the	top	ten	upregulated	miRNAs	were	
hsa‐miR‐124‐3p,	 hsa‐miR‐379‐5p,	 hsa‐miR‐3655,	 hsa‐miR‐450b‐5p,	 hsa‐miR‐29a‐
5p,	 hsa‐miR‐200a‐3p,	 hsa‐miR‐542‐3p,	 hsa‐miR‐138‐5p,	 hsa‐miR‐219a‐2‐3p,	 and	
hsa‐miR‐4701‐3p,	 and	 the	 top	 ten	 downregulated	 miRNAs	 were	 hsa‐miR‐34c‐5p,	
hsa‐miR‐135a‐5p,	 hsa‐miR‐132‐3p,	 hsa‐miR‐3178,	 hsa‐miR‐4449,	 hsa‐miR‐4999‐3p,	
hsa‐miR‐1246,	hsa‐miR‐4424,	hsa‐miR‐1252‐5p,	and	hsa‐miR‐24‐2‐5p.	RT‐PCR	veri‐
fication	of	the	12	miRNAs	revealed	that	5	of	8	upregulated	miRNAs,	2	of	4	down‐
regulated	miRNAs	showed	a	significant	difference	between	the	cases	and	controls	
(P	<	.05).	A	large	number	of	target	genes	and	their	functional	set	showed	overlapping	
among	 the	453	predicted	 target	genes	of	 the	12	miRNAs	 (P	<	 .01).	RT‐PCR	 in	 the	
large	sample	confirmed	the	significant	differential	expression	level	of	hsa‐miR‐29a‐
5p,	 hsa‐miR‐135a‐5p,	 hsa‐miR‐542‐3p,	 and	 hsa‐miR‐4491	between	 cases	 and	 con‐
trols (P	<	.05),	and	three	of	these	microRNA,	except	hsa‐miR‐29a‐5p,	were	significant	
after Bonferroni correction for adjustment of multiple comparisons.
Conclusion: There	was	a	significant	difference	in	miRNAs	expression	in	the	periph‐
eral	blood	between	lung	cancer	patients	and	healthy	controls,	and	4	miRNAs	were	
validated	by	a	large‐size	sample.
K E Y W O R D S
lung	cancer,	miRNA	array	chip,	real‐time	fluorescent	quantitative	PCR	(RT‐PCR)
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1  | INTRODUC TION
Lung	cancer	is	a	common	malignant	tumor.	According	to	the	Chronic	
Disease	Monitoring	Report	of	the	Zhejiang	Province	(2017),	the	inci‐
dence	 rate	 of	 lung	 cancer	was	80.51/100	000,	 and	84.72/100	000	
in	 the	 city,	 and	 78.16/100	 000	 in	 the	 countryside,	 as	 well	 as	
99.37/100	 000	 among	males,	 and	 61.33/100	 000	 among	 females.1 
Lung	cancer	is	ranked	as	the	first	cause	of	cancer‐related	death	in	the	
Zhejiang	Province.	A	total	of	26	788	deaths	were	reported	in	2017,	and	
the	 reported	mortality	 rate	was	55.65/100	000.	The	 reported	mor‐
tality rates in the city and the countryside were 52.04/100 000 and 
58.03/100	000,	respectively.	The	mortality	of	 lung	cancer	 increases	
with	 age;	 the	mortality	 rate	 among	 the	 elderly	 (>65	 years)	 reached	
299.2/100 000.1 These alarming incidence rate and mortality of lung 
cancer	statistics	may	due	to	the	lack	of	effective	early	diagnostic	meth‐
ods	of	lung	cancer.	Currently,	surgical	resection	is	the	main	effective	
therapy	for	lung	cancer.	However,	most	lung	cancer	patients	have	lost	
the	chances	for	surgery	for	quite	of	them	are	not	diagnosed	until	at	
metastatic or even advanced stages.2	Therefore,	it	is	crucial	to	explore	
potential molecular targets for early detection or intervention/treat‐
ment	of	lung	cancer,	thereby	reducing	the	mortality	of	lung	cancer.
MicroRNA	 (miRNA)	 is	 a	 widespread	 class	 of	 non‐coding	 small	
RNA,	 and	 its	mature	 state	 is	 a	 kind	 of	 single‐chain	 small	molecule	
RNA	with	a	length	of	about	19‐23	nucleotides.	Mature	miRNA	mainly	
inhibits	the	translation	of	target	mRNA	by	the	complementary	base	
pairing	of	3‐untranslated	region	(UTR),	5‐UTR	and	the	coding	region	
of	target	mRNA,	which	regulates	the	expression	of	target	genes	at	the	
post‐transcriptional	level.	The	study	of	bioinformatics	has	shown	that	
single	miRNA	molecules	can	bind	to	hundreds	of	target	mRNAs	with	
different functions and play regulatory roles in almost all mammalian 
pathological	and	physiological	activities,	such	as	individual	develop‐
ment,	 tissue	 differentiation,	 cell	 apoptosis,	 and	 energy	metabolism	
and are closely associated with the occurrence and development of 
diseases.	In	recent	years,	some	studies	reported	that	serum/plasma	
miRNA	 expression	 profile	 could	 effectively	 distinguish	 between	
cancer patients and healthy individuals and might be related to the 
development of lung cancer3‐5 or might have potential clinical value 
in	the	early	diagnosis,	prognostic,	and	therapeutic	of	lung	cancer.6‐10 
However,	the	functions	of	miRNA	remain	unclear.	Therefore,	we	used	
a	miRNA	chip	screening	system	for	lung	cancer,	and	then,	real‐time	
fluorescent	quantitative	PCR	(RT‐PCR)	verification	method	to	investi‐
gate	the	difference	of	plasma	miRNA	expression	profile	between	lung	
cancer patients and healthy controls to predict target genes and to 
analyze	the	signal	pathways,	and	to	explore	the	relationship	between	
miRNA	and	the	genesis	and	the	development	of	lung	cancer.
2  | SUBJEC TS AND METHODS
2.1 | Subjects
A	 total	 of	 145	 lung	 adenocarcinoma	patients	were	 recruited	 from	
various	 county‐level	hospitals	 in	 the	Zhejiang	Province,	diagnosed	
with	first	primary	lung	cancer	(confirmed	by	histopathology),	Most	
of	the	stages	for	the	lung	cancer	cases	are	either	T1	or	T2.	Not	all	
the	stages	for	the	lung	cancer	cases	are	available,	although	we	made	
great efforts to collect. The reason might be that some patients’ his‐
tology	and	stages	were	diagnosed	in	hospitals	of	other	provinces	like	
Shanghai,	but	treated	at	their	local	hospitals	without	diagnostic	ma‐
terials in medical records.
Patients	 did	 not	 receive	 any	 surgery,	 chemotherapy,	 or	 ra‐
diotherapy	 before	 fasting	 venous	 blood	 collection.	 Healthy	 in‐
dividuals	 (without	 any	 kind	 of	 cancer,	 frequency	 matched	 with	
cases by age [±5 years] and gender) for chronic disease screen‐
ing were recruited from the community during the same period 
and	fasting	venous	blood	were	collected.	Participants	were	asked	
about	 their	 smoking	 status.	Those	who	 responded	as	 abstained	
smoking	means	they	smoked	but	abstained	for	more	than	1	year.	
Occasionally	 smoking	 was	 defined	 as	 those	 who	 occasionally	
smokes	 but	 does	 not	 meet	 the	 frequently	 smoking	 standard.	
Frequently	smoking	was	defined	as	smoking	every	day	for	more	
than	 1	 year.	 People	 who	 did	 not	 smoke	were	 defined	 as	 never	
smokers.
For	microarray	chip	screening,	we	first	randomly	selected	three	
patients,	 who	 were	 frequency	 matched	 with	 three	 randomly	 se‐
lected healthy individuals from the community during the same pe‐
riod (matched with age [±5 years] and gender). The six blood samples 
of the three patients and three healthy individuals were used first 
for	microarray	chip	screening	of	differentially	expressed	miRNAs,	
then	for	validation	by	RT‐PCR.	The	information	on	the	three	cases	
and three controls is as follows: (a) all three cases were diagnosed 
as having adenocarcinoma of the lung; (b) in the three patients and 
three	healthy	individuals,	the	male/female	rations	are	both	2/1,	and	
the	ages	are	61	±	12	and	62	±	10	years	for	cases	and	controls,	re‐
spectively;	(c)	one	lung	cancer	patients	were	smoker	matched	with	
one	smoking	healthy	control,	the	other	4	participants	are	all	never	
smokers.	The	differences	 in	the	age	and	gender	between	the	two	
groups were not significant.
In	 the	second	stage,	all	 the	blood	samples	of	 the	145	 lung	ad‐
enocarcinoma	 patients’	 and	 frequency‐matched	 55	 healthy	 indi‐
viduals’ were used for a larger sample validation of differentially 
expressed	miRNAs	by	RT‐PCR.	The	age,	gender	distribution,	family	
history	of	lung	cancer	and	smoking	status	of	participants	are	shown	
in	Table	1,	 and	no	 significant	differences	were	observed	between	
the two groups.
2.2 | Experimental procedures
2.2.1 | RNA extraction and quality control
Plasma	RNA	was	extracted	by	the	TRIzol	method	and	purified	with	
RNasey	Mini	Kit	 (Qiagen).	NanoDrop	ND‐1000	(Thermo)	was	used	
to	measure	the	concentration	of	purified	RNA	and	detect	the	quality	
of	RNA.	The	integrity	of	the	RNA	was	detected	by	denaturing	aga‐
rose gel electrophoresis.
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2.2.2 | RNA labeling and microarray chip 
hybridization
RNA	labeling	and	microarray	chip	hybridization	were	performed	ac‐
cording	to	the	method	and	instructions	provided	by	Exiqon	(Exiqon	
A/S	Skelstedet	162950).
2.2.3 | Microarray chip scanning
Microarray	 chip	 scanning	 was	 performed	 by	 using	 Axon	 GenePix	
4000B microarray chip scanner (Molecular Devices) according to the 
manufacturer's instructions.
2.2.4 | Real‐time fluorescent quantitative PCR 
verification (RT‐PCR)
The	cDNA	synthesis	of	both	target	miRNA	and	reference	miRNA	(hsa‐
miR‐93‐5p)	was	performed	after	quality	 inspection	and	used	 for	RT‐
PCR,	respectively.	The	volume	of	reaction	was	10	µL.	The	detection	of	
target	miRNA	and	reference	hsa‐miR‐93‐5p	was	performed	according	
to	the	following	procedure:	95°C	for	10	minutes;	then,	40	cycles	of	each	
(95°C	for	10	seconds,	60°C	for	60	seconds	[fluorescence	collection]).	
The	melting	curve	of	RT‐PCR	products	was	established	according	to	the	
following	procedure:	95°C	for	10	seconds,	60°C	for	60	seconds,	and	
95°C	for	15	seconds	after	amplification.	Then	slowly	heated	from	60	to	
99°C (Ramp Rate was automatically set to 0.05°C/s by the instrument).
The	expression	of	 target	miRNA	was	corrected	with	 reference	
miRNA.	The	volume	of	2	µL	was	used	for	each	sample	for	RT‐PCR.	
The	hsa‐miR‐93‐5p	(the	expression	level	is	constant	among	different	
samples)	was	used	as	a	reference.	The	sequences	of	related	primers	
are shown in Table 2.
2.3 | Target gene prediction
Target gene prediction was performed by using the information of 
three	database	 tools	 including	miRbase,	miRanda,	and	TargetScan.	
TopGO	analysis	was	performed	for	the	target	genes.
2.4 | The methods for data analysis
All	data	were	analyzed	using	SPSS	13.0	software.	The	continu‐
ous variables were presented as the means ± SD. The univariate 
logistic regression analysis was performed to assess associa‐
tions	with	gender,	age,	family	history	of	lung	cancer	and	smoking	
(multi‐categorical	 variables	 transformed	 into	 dummy	 variables)	
between	the	cases	and	controls,	and	group	variable	 (cases	=	1,	
controls	 =	 0)	 was	 used	 as	 the	 dependent	 variable	 (sls	 =	 0.1,	
sle	=	0.05).
2.5 | Analysis of miRNA expression profiling
The	 microarray	 chip	 scanning	 image	 was	 read	 by	 using	 GenePix	
Pro	6.0	(Molecular	Devices),	and	the	signal	value	of	the	probes	was	
extracted.	The	Exiqon	miRCURY	LNA™	microRNA	microarray	chip	
contains	3100	probes,	covering	all	human,	mouse,	and	rat	microRNA	
annotated	by	miRbase	18.0	and	also	the	viral	microRNA	related	to	
these species.
Each	probe	has	four	repeats	on	the	microarray	chip,	retaining	
the	 probes	with	 value	 ≥30.0	 in	 all	 samples	 and	 calculating	 the	
median	value.	All	of	 the	probes	with	 the	 signal	 value	≥30	were	
screened	for	median	value	standardization	among	the	microarray	
chips	to	obtain	the	standardized	data,	and	the	differentially	ex‐
pressed	probes	were	screened.	Standardization	can	minimize	the	
system error among microarray chips so that different microar‐
ray	chips	are	comparable.	Fold	change	and	P‐value	were	used	in	
this	 experiment	 for	 miRNAs	 selection	 with	 Fold	 Change	 ≥2.0,	
P‐value	≤	.05.
2.6 | Results analysis of the RT‐PCR for verification
The	results	of	the	RT‐PCR	for	verification	were	analyzed	by	using	2−
ΔΔCT	method.	Lung	cancer	cases	group	2−ΔΔCT/Healthy	control	group	
2−ΔΔCT	>	1	was	considered	as	upregulation.	Lung	cancer	cases	group	
2−ΔΔCT/Healthy	control	 group	2−ΔΔCT < 1 was considered as down‐
regulation. P	≤	.05	was	considered	as	significant.
Subjects
Lung cancer pa‐
tients (145) Healthy controls (55) ORc (95% CI)
Gender	(M/F) 100/45 30/25 1.852	(0.980‐3.501)
Age	(year) 62	±	11 65	±	13 1.022	(0.993‐1.051)
Family	history	of	lung	cancer
No	=	0 135 54 1.00
Yes	=	1 10 1 0.250	(0.031‐2.001)
Smoking
Never 63 44 1.00
Abstained 63 0 1.187	(0.497‐2.836)
Occasionally 2 1 0.000 (0.000)
Frequently 17 10 0.850	(0.068‐10.610)
Abbreviation:	ORc:	Crude	OR.
TA B L E  1  General	information	of	the	
study subjects for verification by using 
fluorescent	quantitative	PCR	in	large	
sample
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2.7 | Target gene prediction and signaling 
pathway analysis
2.7.1 | Target gene prediction
Target gene prediction was performed by using the information of 
three	databases	 including	miRbase,	miRanda,	and	TargetScan.	The	
overlapping part of the predictive results derived from the three da‐
tabases was defined as the final prediction results. The association 
strength	 of	 the	 Overlap	 number	 >3	 and	 Overlap‐coefficient	 >0.5	
was used as the default screening index.
2.7.2 | Gene ontology (GO) analysis
The	GO	project	provides	a	controlled	vocabulary	to	describe	gene	
and gene product attributes in any organism.11 The ontology cov‐
ers	three	domains:	Biological	Process	(BP),	Cellular	Component	(CC),	
and	Molecular	Function	 (MF).	Fisher's	 exact	 test	 is	used	 to	 find	 if	
there	 is	more	overlap	between	the	DE	 list	and	the	GO	annotation	
list than would be expected by chance. The P‐value denotes the sig‐
nificance	of	GO	terms	enrichment	 in	the	DE	genes.	The	 lower	the	
P‐value,	the	more	significant	the	GO	Term	(to	our	above	described	
12	miRNAs,	P‐	value	≤	.01	was	selected).
TA B L E  2  List	of	primers	for	real‐time	quantitative	PCR	and	the	results	of	fluorescent	quantitative	PCR	verification
Genes Primers
Annealing tempera‐
ture (°C)
Product 
length (bp)
Fold change (lung cancer  
case group vs healthy  
control group) P value
hsa‐miR‐93‐5p GSP:5′GGCAAAGTGCTGTTCGTG3′ 60 65   
R:5′CAGTGCGTGTCGTGGAGT3′
Upregulated	miRNAs
hsa‐miR‐3655 GSP:5′AGGCTTGTCGCTGCGGT3′ 60 61 0.77 .320
R:5′GTGCGTGTCGTGGAGTCG3′
hsa‐miR‐450b‐5p GSP:5′GGGGTTTTGCAATATGTTCC3′ 60 64 1.53 .003*
R:5′GTGCGTGTCGTGGAGTCG3′
hsa‐miR‐29a‐5p GSP:5′GGGACTGATTTCTTTTGGT3′ 60 65 4.08 .003*
R:5′CAGTGCGTGTCGTGGA3′
hsa‐miR‐542‐3p GSP:	5′GGGGTGTGACAGATTGATAA3′ 60 66 1.79 .014*
R:5′CAGTGCGTGTCGTGGAGT3′
hsa‐miR‐138‐5p GSP:5′GGGGCTGGTGTTGTGAATC3′ 60 63 1.56 .045*
R:5′GTGCGTGTCGTGGAGTCG3′
hsa‐miR‐502‐5p GSP:5′GGGGAATCCTTGCTATCTGG3′ 60 64 0.99 .946
R:5′GTGCGTGTCGTGGAGTCG3′
hsa‐miR‐4491 GSP:5′GGGGAATGTGGACTGGTGTG3′ 60 64 2.21 .034*
R:5′GTGCGTGTCGTGGAGTCG3′
hsa‐miR‐192‐5p GSP:5′GGGGCTGACCTATGAATTG3′ 60 65 1.78 .097
R:5′CAGTGCGTGTCGTGGAGT3′
Downregulated	miRNA
hsa‐miR‐34c‐5p GSP:5′GGGAGGCAGTGTAGTTAGC3′ 60 66 0.69 .148
R:5′CAGTGCGTGTCGTGGAGT3′
hsa‐miR‐135a‐5p GSP:5′GGGGTATGGCTTTTTATTCCT3′ 60 65 0.23 .002*
R:5′GTGCGTGTCGTGGAGTCG3′
hsa‐miR‐1246 GSP:5′GGGGAATGGATTTTTGG3′ 60 63 0.23 .016*
R:5′CAGTGCGTGTCGTGGAG3′
hsa‐miR‐125a‐5p GSP:5′GCTCCCTGAGACCCTTTA3′ 60 66 0.15 .058
R:5′CAGTGCGTGTCGTGGAGT3′
Note: GSP	is	the	specific	primer	corresponding	to	miRNA;	R	is	the	primer	that	matched	with	RT	primer.	The	fold	change	of	lung	cancer	case	group	vs	
healthy	control	group	>1	was	considered	as	upregulation,	and	<1	was	considered	as	downregulation.
*Indicates P	≤	.05	(significant).	
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2.7.3 | Signaling pathway analysis
Pathway analysis is a functional analysis of mapping genes to 
Kyoto	Encyclopedia	of	Genes	and	Genomes	(KEGG)	pathways.	The	
P‐value	was	calculated	by	the	Fisher	Exact	Test	that	denotes	the	
significance	 of	 the	 pathway	 correlated	 to	 the	 conditions.	 Lower	
the P‐value,	more	significant	 is	the	pathway.	P < .05 was used in 
our	study	as	the	threshold	to	obtain	the	high‐frequency	annota‐
tion,	 signaling	 transduction,	 and	 disease‐related	 pathway	 of	 the	
gene	set.	miRNA_GO_Network	map	was	drawn	by	using	gene	sets	
correlation	analysis	 from	the	miRNA	and	BP	enrichment	analysis	
in	GO.
3  | RESULTS
3.1 | Preliminary screening of miRNA Array chip
Three	 hundred	 and	 thirty‐eight	 differentially	 expressed	 miRNAs	
were	 identified	 through	 initial	 microarray	 chip	 analysis.	 Among	
them,	204	were	significantly	upregulated,	and	134	were	significantly	
downregulated	(Fold	Change	≥2.0,	P‐value	≤	.05).	According	to	the	
fold	changes,	the	top	ten	upregulated	miRNAs	were	hsa‐miR‐124‐3p,	
hsa‐miR‐379‐5p,	hsa‐miR‐3655,	hsa‐miR‐450b‐5p,	hsa‐miR‐29a‐5p,	
hsa‐miR‐200a‐3p,	hsa‐miR‐542‐3p,	hsa‐miR‐138‐5p,	hsa‐miR‐219a‐
2‐3p,	 and	 hsa‐miR‐4701‐3p,	 and	 the	 top	 ten	 downregulated	 miR‐
NAs	 were	 hsa‐miR‐34c‐5p,	 hsa‐miR‐135a‐5p,	 hsa‐miR‐132‐3p,	
hsa‐miR‐3178,	hsa‐miR‐4449,	hsa‐miR‐4999‐3p,	hsa‐miR‐1246,	hsa‐
miR‐4424,	hsa‐miR‐1252‐5p,	and	hsa‐miR‐24‐2‐5p.
3.2 | RT‐PCR verification
According	to	the	microarray	chip	screening	results	and	literature	re‐
ports,	12	miRNAs	(Table	2)	were	then	selected	for	the	verification	
by	using	RT‐PCR.
The	results	of	 the	RT‐PCR	verification	showed	that	among	the	
chosen	12	miRNAs,	5	of	8	significantly	upregulated	miRNAs	showed	
significant difference between the lung cancer group and the 
healthy control group (P	<	.05,	all	of	them	were	upregulated);	2	of	4	
significantly	downregulated	miRNAs	showed	significant	difference	
between the two groups (P	<	.05,	both	of	them	kept	downregulated)	
(Table 2). The amplification and melting curves (not shown in paper) 
showed	that	the	RT‐PCR	reaction	had	good	amplification	efficiency	
and specificity.
3.3 | Target gene prediction
The overlapping part of the predictive results derived from three da‐
tabases	including	miRbase,	miRanda,	and	TargetScan	were	selected,	
which	 showed	 a	 total	 of	 eight	miRNAs	 in	 the	 overlapping	 part	 of	
predictive results derived from the three databases. The eight miR‐
NAs	and	the	number	of	their	predictive	target	genes	were	as	follows:	
hsa‐miR‐125a‐5p	with	102	 target	genes,	hsa‐miR‐135a‐5p	with	91	
target	genes,	hsa‐miR‐138‐5p	with	45	target	genes,	hsa‐miR‐192‐5p	
with	 22	 target	 genes,	 hsa‐miR‐34c‐5p	with	 64	 target	 genes,	 hsa‐
miR‐450b‐5p	with	67	target	genes,	hsa‐miR‐502‐5p	with	27	target	
genes,	and	hsa‐miR‐542‐3p	with	35	target	genes,	for	a	total	of	453	
target	genes	(Figure	not	shown).	GO	and	signaling	pathway	enrich‐
ment analysis of the predictive 453 target genes were performed.
3.4 | GO analysis and GO cluster enrichment 
analysis of predictive target genes
The	GO	analysis	showed	a	 large	amount	of	 functional	overlapping	
among	 the	453	predicted	 target	genes.	 In	addition,	 they	were	en‐
riched	in	BP	including	cellular	macromolecule	metabolic	process,	cell	
cycle	regulation,	cellular	protein	metabolic	process,	positive	regula‐
tion	of	the	BP,	cellular	protein	modification	process,	and	intracellular	
signal	 transduction;	 in	 the	 CC	 including	 intracellular,	 intercellular,	
cytoplasm,	organelle	part,	ion	channel	complex,	and	stress	fiber;	and	
in	the	MF	including	protein	binding,	nucleotide	binding,	and	protein	
kinase	activity,	(P < .01) (Tables 3).
3.5 | Enrichment analysis of signaling 
transduction pathway
Pathway	enrichment	analysis	based	on	KEGG	was	performed	on	the	
predictive	target	genes	set	through	DAVID	database	and	the	sign‐
aling pathways with P	 <	 .05	were	 selected	 (Figure	 1).	 The	 results	
showed a large amount of overlapping among the signaling trans‐
duction	pathways	of	predictive	target	genes	set.	The	KEGG	pathway	
analysis	 involved	 several	 disease‐related	 pathways	 including	 tran‐
scriptional	misregulation	in	cancer,	proteoglycans	in	cancer,	mRNA	
surveillance	 pathway,	 RNA	 degradation,	 cAMP	 signaling	 pathway,	
dopaminergic	 synapses,	 and	 vascular	 smooth	 muscle	 contraction	
(P < .05) (Table 4).
3.6 | Validation by RT‐PCR
According	to	the	screening	results	by	microarray,	the	RT‐PCR	veri‐
fication results of microarray chip samples and the literature re‐
ports,	 four	 miRNAs	 including	 hsa‐miR‐29a‐5p,	 hsa‐miR‐135a‐5p,	
hsa‐miR‐542‐3p,	and	hsa‐miR‐4491	were	selected	for	differentially	
expressed	miRNAs	verification	by	RT‐PCR	in	a	large	sample	of	145	
first‐episode	lung	cancer	patients	and	55	healthy	controls.	The	ex‐
perimental	approaches,	reference	genes,	and	data	analysis	methods	
were	the	same	as	the	RT‐PCR	validation	experiments	in	the	microar‐
ray chip samples. The results showed that the difference of expres‐
sion	 level	 of	 hsa‐miR‐29a‐5p,	 hsa‐miR‐135a‐5p,	 hsa‐miR‐542‐3p,	
and	hsa‐miR‐4491	between	the	lung	cancer	group	and	the	control	
group showed significance (P	<	.05),	which	were	in	accordance	with	
the upregulation/downregulation trend of the screening results by 
microarray	 and	 the	RT‐PCR	 verification	 results	 of	microarray	 chip	
samples	(Figure	2).
Multiple comparisons might lead to false positives. We con‐
ducted multistage of validations among large samples of cases 
and controls in order to reduce potential multiple comparison 
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false‐positive	issues.	We	have	attempted	using	a	2‐stage	approach.	
In	 the	 discovery	 stage,	 we	 identified	 338	 differentially	 expressed	
microRNAs,	but	only	12	microRNAs	were	 identified	 in	 the	 further	
PCR confirmation. We were not able to adjust for multiple compar‐
isons	because	of	 relatively	 small	 sample	 size.	 In	 the	 confirmation/
validation	 stage,	 among	 12	 microRNAs,	 we	 eventually	 identified	
four	microRNAs	with	P‐value	<.05.	If	we	use	Bonferroni	correction	
(0.05/12	 =	 0.00417),	 three	microRNAs	 are	 statistically	 significant	
hsa‐miR‐542‐3p,	hsa‐miR‐4491,	and	hsa‐miR‐135a‐5p.
4  | DISCUSSION
Studies	have	shown	that	miRNAs	are	abnormally	expressed	in	a	va‐
riety	of	tumors	such	as	lung	cancer,5‐7,10,12	breast	cancer,13 and liver 
cancer.14	More	than	50%	of	the	miRNA	genes	have	been	located	in	
tumor‐related	genomic	regions	or	fragile	sites.15	The	miRNAs	can	act	
not only as tumor suppressor genes to downregulate the activity on‐
cogenes but also to downregulate the activity of tumor suppressor 
genes.	miRNAs	can	also	affect	the	development	and	progression	of	
tumors	by	intervening	cell	cycle,	apoptosis,	angiogenesis,	and	metas‐
tasis.9,16,17	So	far,	only	a	very	few	of	the	miRNAs	and	their	regulating	
target	genes	had	been	identified,	and	the	functions	of	most	miRNAs	
were	 still	 unclear.	 Further	 studies	 are	needed	on	 the	 functions	of	
miRNAs	to	search	for	new	miRNAs	to	accurately	predict	their	target	
genes	and	correctly	understand	the	 interactions	of	miRNA	and	 its	
target genes.
To	date,	 the	 total	number	of	miRNAs	 that	was	 included	 in	 the	
latest version of miRbase22.1 database11 had exceeded 38 000 pre‐
cursor	sequences,	and	a	total	of	mature	miR	and	miR*	products	of	
TA B L E  3  The	Gene	Ontology	(GO)	biological	process	(BP),	cellular	component	(CC),	and	molecular	function	(MF)	analysis	of	target	genes
GO.ID Term Category
The number of target 
genes P value
GO:0044260 Cellular macromolecule metabolic 
process
BP 237 1.53207E‐06
GO:0007049 Cell cycle BP 70 1.61085E‐06
GO:0048522 Positive regulation of cellular process BP 148 1.63651E‐06
GO:0044267 Cellular protein metabolic process BP 153 2.91601E‐06
GO:0048518 Positive regulation of biological process BP 165 4.43874E‐06
GO:0006464 Cellular protein modification process BP 123 5.37341E‐06
GO:0036211 Protein modification process BP 123 5.37341E‐06
GO:0035556 Intracellular signal transduction BP 94 1.08515E‐05
GO:0022402 Cell cycle process BP 54 1.64587E‐05
GO:0006793 Phosphorus metabolic process BP 103 1.85407E‐05
GO:0005622 Intracellular CC 346 1.24301E‐06
GO:0044424 Intracellular part CC 338 3.26228E‐06
GO:0005623 Cell CC 379 3.83014E‐05
GO:0044464 Cell part CC 377 0.000112113
GO:0005737 Cytoplasm CC 269 0.000131442
GO:0005829 Cytosol CC 99 0.00020604
GO:0044422 Organelle part CC 212 0.000559938
GO:0043229 Intracellular organelle CC 290 0.000657913
GO:0034702 Ion channel complex CC 16 0.000695189
GO:0001725 Stress fiber CC 6 0.000864451
GO:0032553 Ribonucleotide binding MF 68 4.09233E‐05
GO:0005515 Protein binding MF 272 4.68665E‐05
GO:0032555 Purine ribonucleotide binding MF 67 5.7016E‐05
GO:0017076 Purine nucleotide binding MF 67 6.72523E‐05
GO:0000166 Nucleotide	binding MF 78 0.000151141
GO:1901265 Nucleoside	phosphate	binding MF 78 0.000153272
GO:0004672 Protein	kinase	activity MF 28 0.000184924
GO:0032550 Purine ribonucleoside binding MF 64 0.000193572
GO:0001883 Purine nucleoside binding MF 64 0.000202749
GO:0032549 Ribonucleoside binding MF 64 0.000202749
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48	885	covering	a	total	of	168	species	in	mirbase18.0	that	are	men‐
tioned	in	this	article.	With	the	development	of	a	high‐throughput	de‐
tection	technology	of	miRNA,	an	increasing	number	of	new	miRNA	
have been discovered. The ambiguous and incorrectly commented 
sequences	 in	miRbase	 database	were	 constantly	 cleared,	 and	 the	
reliability	of	 the	database	was	continuously	 improved.	MiRNA	mi‐
croarray	 is	 the	most	 commonly	 used	method	 for	 high‐throughput	
detection	 of	 large	 amount	 of	miRNA	 specific	 expression	 in	 tumor	
samples.18	Compared	with	traditional	RNA	analysis	methods,	it	has	
the	 following	 advantages:	 (a)	 high‐throughput	 joint	 detection;	 (b)	
the detection efficiency and sensitivity are high; and (c) sample de‐
manded	 is	 small,	 and	only	1	µg	of	 total	RNA	can	complete	all	 the	
tests,	which	has	 great	 significance	 for	 tumor	 samples	 that	 are	 ex‐
tremely difficult to obtain.
F I G U R E  1  miRNA_GO_Network	analysis
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As	a	 research	method	of	expression	 spectroscopy,	 it	 is	diffi‐
cult	to	avoid	false‐positive	results	for	the	miRNA	chip.	Therefore,	
it	 is	necessary	to	verify	the	chip	screened	miRNA.	Although	RT‐
PCR	is	a	low‐throughput	detection	method,	it	has	high	detection	
sensitivity	and	can	 faithfully	 reflect	 the	abundance	of	miRNA	 in	
samples.	Further,	RT‐PCR	verification	of	 large	samples	can	more	
truly	 reflect	 the	 actual	 expression	 of	 miRNA.	 Accordingly,	 the	
quality	controls	 in	the	RT‐PCR	analysis	are	very	 important,	as	 in	
our	 study,	 we	 (a)	 measured	 the	 concentration	 of	 purified	 RNA	
and	detected	the	quality	of	RNA	before	RT‐PCR	analysis,	(b)	used	
hsa‐miR‐93‐5p	as	a	reference	and	the	expression	of	target	miRNA	
was	corrected	with	 reference	miRNA,	 (c)	The	negative	 template	
control	was	performed	in	the	RT‐PCR	analysis,	(d)	melt	curve	and	
application curve are used to determine the specificity of the 
products,	 (e)	 the	results	of	 the	RT‐PCR	for	verification	were	an‐
alyzed	 by	 using	 2−ΔΔCT method and the differentially expressed 
probes were screened.
General	 human	 tissue	 could	 express	 miRNA,	 studies	 also	
showed	that	miRNA	might	not	be	degraded	by	endogenous	RNase	
in serum and plasma and could still exist in a very stable form in 
harsh	conditions	 (such	as	high	 temperature,	 low	or	high	pH	envi‐
ronment,	 and	 multiple	 freeze‐thaw).	 Moreover,	 the	 expression	
profiles	of	miRNA	 in	 the	serum	and	plasma	of	normal	people	and	
patients with different diseases would be specifically changing 
with	 the	 physiological	 status,	 disease	 type,	 and	 disease	 courses.	
Based	 on	 this,	 this	 study	 used	microRNA	 chip	with	 3100	 probes	
and	screened	out	a	total	of	338	miRNAs	which	are	differentially	ex‐
pressed	in	lung	cancer	patients	and	healthy	controls.	Among	them,	
204	miRNAs	were	 significantly	 increased,	 and	134	miRNAs	were	
significantly	downregulated.	In	the	12	miRNAs	which	were	verified	
by	RT‐PCR,	seven	miRNAs	were	confirmed.	RT‐PCR	validation	re‐
sults	of	large	samples	suggested	hsa‐miR‐29a‐5p,	hsa‐miR‐135a‐5p,	
hsa‐miR‐542‐3p,	 and	 hsa‐miR‐4491	 could	 be	 used	 as	 candidate	
genes	 for	 early	 screening	 of	 lung	 cancer,	 and	 three	 of	 these	mi‐
croRNAs,	except	hsa‐miR‐29a‐5p,	were	significant	after	Bonferroni	
correction for adjustment of multiple comparisons. These results 
illustrated	 that	RT‐PCR	verification	 results	were	highly	consistent	
with	miRNA	chip	results,	suggesting	that	miRNA	chip	detection	is	
an	efficient,	rapid,	and	high‐throughput	method	for	the	analysis	of	
miRNA	 differential	 expression	 between	 lung	 cancer	 patients	 and	
healthy	controls,	while	RT‐PCR	is	suitable	for	the	study	of	individual	
gene expression changes. The two methods could complement and 
confirm each other.
Previous	studies	showed	that	miRNA	family	is	an	important	part	
of	the	gene	expression	regulatory	network	and	might	be	involved	in	
the regulation of multiple signaling pathways.19‐21 The determination 
of	miRNA	target	gene	was	the	key	to	study	the	biological	function	
of	miRNA,	and	the	functional	analysis	of	target	gene	was	helpful	to	
understand	 the	 functional	 mechanism	 of	 miRNA.	 Bioinformatics	
prediction	 showed	 that	miRNAs	could	 regulate	more	 than	30%	of	
protein‐coding	genes.22	An	individual	miRNA	could	act	on	a	number	
of	target	genes	to	regulate	biological	processes,	while	multiple	miR‐
NAs	could	also	regulate	some	of	the	target	genes.	Through	the	analy‐
sis,	12	differentially	expressed	miRNAs	that	we	selected	participated	
in the regulation of 37 281 predicted target genes and functioned in 
a	 variety	of	 physiological	 processes.	 Further	 analysis	 showed	 that	
PathwayID Definition
The number of 
target genes P value
hsa03015 mRNA	surveillance	pathway—Homo	sapiens	
(human)
8 .00173546
hsa04728 Dopaminergic	synapse—Homo	sapiens	
(human)
9 .004934847
hsa04270 Vascular	smooth	muscle	contraction—Homo	
sapiens (human)
8 .009863016
hsa04261 Adrenergic	signaling	in	cardiomyocytes—
Homo	sapiens	(human)
9 .0111802
hsa05205 Proteoglycans	in	cancer—Homo	sapiens	
(human)
11 .01188643
hsa05202 Transcriptional	misregulation	in	cancer—
Homo	sapiens	(human)
10 .01285791
hsa04360 Axon	guidance—Homo	sapiens	(human) 8 .01298216
hsa03013 RNA	transport—Homo	sapiens	(human) 9 .02525796
hsa04024 cAMP	signaling	pathway—Homo	sapiens	
(human)
10 .02583363
hsa04713 Circadian	entrainment—Homo	sapiens	
(human)
6 .0322689
hsa00052 Galactose	metabolism—Homo	sapiens	
(human)
3 .0367944
hsa03018 RNA	degradation—Homo	sapiens	(human) 5 .04100519
TA B L E  4   The Enrichment analysis of 
signaling transduction pathway
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the	12	miRNAs	had	453	overlapped	predicted	target	genes;	through	
the	analysis	of	target	genes,	we	found	that	the	collection	functions	
of target genes were also highly coincident suggesting that the reg‐
ulation	of	target	genes	by	miRNA	had	a	synergistic	effect.	When	a	
few	miRNAs	were	commonly	upregulated	in	tissues,	the	inhibition	of	
a	target	gene	would	be	strengthened,	and	vice	versa.
The	 KEGG	 pathway	 analysis	 showed	 a	 large	 amount	 of	 over‐
lapping	among	the	signal	transduction	pathway	of	target	gene	sets,	
which	are	involved	in	cancer	transcriptional	dysregulation	pathway,	
proteoglycan,	and	cancer	pathway,	suggesting	that	it	might	be	closely	
related to the cancers such as lung cancer. Studies suggested that 
hsa‐miR‐29a	 family	 could	 inhibit	 the	 protein	 expression	 of	 B7‐H3	
and	perform	inhibition	effects	on	a	variety	of	B7‐H3	protein‐medi‐
ated	solid	tumors,	including	lung	cancer,	and	hsa‐miR‐29a	mutation	
could promote the growth of tumor cells23;	hsa‐miR‐29a	in	the	pe‐
ripheral circulation in lung cancer patients could bind and activate 
toll‐like	 receptors	 (TLR)	 in	 immune	cells	around	tumors.	Activation	
of	TLRs	could	trigger	NF‐κB	pathway,	 leading	to	an	increase	in	the	
expressions	of	IL‐6	and	TNF‐α in immune cells and increasing the po‐
tential	for	tumor	growth	and	metastasis,24 which was consistent with 
the	results	of	this	study,	suggesting	that	hsa‐miR‐29a	was	involved	
in	the	pathological	process	of	lung	cancer.	Although	the	relationship	
between	hsa‐miR‐4491	and	lung	cancer	has	not	been	reported,	our	
study suggested that it might play an important role in the patho‐
genesis	 of	 lung	 cancer.	 According	 to	 another	 report,	 miR‐542‐3p	
was	located	in	Xq26.3	and	was	downregulated	in	non–small‐cell	lung	
cancer and breast cancer. It could directly target survival protein or 
angiopoietin‐2,	 respectively,	 resulting	 in	 growth	 arrest	 and	 angio‐
genesis	inhibition.	miR‐542‐3p	acts	as	a	tumor	suppressor	gene,25,26 
which	 is	 inconsistent	 with	 the	 high	 expression	 of	 miR‐542‐3p	 in	
lung	cancer	cases	in	this	study.	Zhang	Hongyan	et	al27 investigated 
miR‐135a	expression	and	clinical	pathology	of	lung	cancer	and	found	
that	miR‐135a	was	closely	related	to	the	clinical	stage	and	patholog‐
ical	grade	of	lung	cancer.	The	serum	miR‐135a	level	was	downreg‐
ulated	 in	non–small‐cell	 lung	carcinoma	 (NSCLC)	patients	and	was	
associated	with	 poor	 prognosis.	 It	 can	be	used	 as	 a	 biomarker	 for	
NSCLC	 prognosis.28	 Zhou's	 findings	 indicated	 that	 miR‐135a	 pro‐
motes	cell	apoptosis	and	 inhibits	cell	proliferation,	migration,	 inva‐
sion,	and	 tumor	angiogenesis	by	 targeting	 IGF‐1	gene	 through	 the	
IGF‐1/PI3K/Akt	signaling	pathway	in	NSCLC,29	and	MiR‐135a	inhib‐
its	migration	and	invasion	and	regulates	EMT‐related	marker	genes	
by	targeting	KLF8	in	lung	cancer	cells,30 which is consistent with our 
study,	while	 Zhang's	 study	 showed	 that	MiR‐135a	 overexpression	
promoted	viability,	migration,	and	 invasion,	but	 inhibited	apoptosis	
of	 NCI‐H1650	 and	 NCI‐H1975	 cells.31	 Our	 subsequent	 cell	 biol‐
ogy experiments supported our results that the overexpression of 
mir‐135a‐5p	could	inhibit	the	invasion	of	adenocarcinoma	cells,	and	
the	overexpression	of	mir‐542‐3p	could	promote	the	proliferation	of	
adenocarcinoma	cells	 (data	not	shown).	Taken	together,	the	results	
suggest that there are divergences in the expression and function 
of	various	miRNAs	 in	 lung	cancer,	which	might	be	due	 to	 that	 the	
upregulation	or	downregulation	of	miRNA	mainly	dependent	on	the	
types	of	tissue	and	the	target	proteins	of	miRNA.	We	cannot	simply	
define	a	specific	miRNA	as	a	tumor	suppressor	gene	or	an	oncogene.	
In	one	cell	system,	 it	may	be	an	oncogene,	while	 in	another	 it	may	
be	a	tumor	suppressor	gene.	And	these	areas	need	further	studies.
In	 summary,	we	 screened	 the	miRNA	expression	profile	which	
was	closely	related	to	 lung	cancer	by	using	miRNA	microarray	and	
bioinformatics	 approaches.	 In	 addition,	 target	 prediction	 showed	
that	lung	cancer‐related	miRNA	targets	were	very	extensive,	involv‐
ing	the	genes	including	oncogenes,	tumor	suppressor	genes,	signal	
transduction	genes,	 and	 cell	 cycle	 regulation	 related	genes,	which	
would provide a new experimental basis and ideas for the further re‐
search	on	the	effect	of	miRNA	on	the	occurrence	and	development	
of lung cancer in future.
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F I G U R E  2  Results	of	the	larger	sample	validation	by	real‐time	
fluorescence	quantitative	PCR	(RT‐PCR).	Note:	tumor	=	lung	cancer	
patients;	normal	=	healthy	controls.	The	fold	change	of	the	lung	
cancer group vs the healthy control group >1 was considered 
as	upregulation,	<1	was	considered	as	downregulation;	*P	≤	.05	
(significant),	***P	≤	.001	(significant),	****P	≤	.0001	(significant)	
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